Vulvar lichen sclerosus-lichen planus overlap: A case series with diagnostic and management implications [0.03%]
外阴扁平苔藓硬化性苔藓混合症：具有诊断和治疗意义的病例系列研究
Makenna Chapman,Maria J Etcheverry,Christina N Kraus
Makenna Chapman
Case Reports
JAAD case reports. 2025 Nov 8:67:129-131. DOI:10.1016/j.jdcr.2025.11.006 2025
Isolated perineal plaque as the initial presentation of pemphigus vulgaris [0.03%]
会阴部皮损作为寻常型天疱疮的首发症状
Aster Workineh,Gauri Panse,Mary Tomayko et al.
Aster Workineh et al.
Successful treatment of Hori nevus with a 755 nm ps alexandrite laser with a diffractive lens array [0.03%]
755nm脉冲alexandrite激光联合衍射光学元件阵列治疗Hori斑临床观察
Kentaro Ishii,Jun Omatsu,Hideki Shimura et al.
Kentaro Ishii et al.
Case Reports
JAAD case reports. 2025 Nov 7:67:168-170. DOI:10.1016/j.jdcr.2025.11.002 2025
Rituximab resistant pemphigus vulgaris successfully treated with obinutuzumab [0.03%]
对利妥昔单抗治疗耐药的寻常型天疱疮采用奥比妥珠单抗治疗获得成功
Marjolein A J Hiel,Gilles F H Diercks,Maria C Bolling et al.
Marjolein A J Hiel et al.
Case Reports
JAAD case reports. 2025 Nov 8:67:132-135. DOI:10.1016/j.jdcr.2025.10.065 2025
Dual immunomodulator therapy with upadacitinib and bimekizumab in severe hidradenitis suppurativa: A case report [0.03%]
重度汗腺炎接受乌帕替尼和比马列单抗联合免疫调节治疗的病例报告
Kenan Kherallah,Claire S Chung,Justin Gillenwater et al.
Kenan Kherallah et al.
Case Reports
JAAD case reports. 2025 Nov 8:67:155-157. DOI:10.1016/j.jdcr.2025.10.066 2025
Trastuzumab-associated prurigo nodularis successfully treated with nemolizumab: A case report [0.03%]
纳莫利珠单抗成功治疗曲妥珠单抗相关结节性痒疹1例报告
Ryan Chen,Michelle S Lee,Ashleigh Eberly Puleo et al.
Ryan Chen et al.
Case Reports
JAAD case reports. 2025 Nov 6:67:126-128. DOI:10.1016/j.jdcr.2025.10.046 2025
Intravenous immunoglobulin for cutaneous chronic graft-versus-host disease [0.03%]
静脉注射免疫球蛋白治疗皮肤慢性移植物抗宿主病
Tien-Heng Chang,Trenton Greif,Jason Nayar et al.
Tien-Heng Chang et al.
Avik Mondal
Avik Mondal
Case Reports
JAAD case reports. 2025 Nov 6:67:117-119. DOI:10.1016/j.jdcr.2025.10.031 2025
Successful treatment of cutaneous sarcoidosis with deucravacitinib, a selective TYK2 inhibitor [0.03%]
用于治疗皮肤结节病的deucravacitinib(TYK2选择性抑制剂)疗法取得成功
Henry O Herrera,Carol Sanchez,Gabrielle Minor et al.
Henry O Herrera et al.
Case Reports
JAAD case reports. 2025 Nov 5:67:165-167. DOI:10.1016/j.jdcr.2025.10.058 2025
Pemphigus herpetiformis: A case report of response to dupilumab after failure of multiple conventional therapies [0.03%]
大疱性表皮松解症合并herpetiformis型天疱疮1例及Dupixent治疗有效报告
Fabiola Pabón-González,Iancarlos Jiménez-Sacarello,José Cuesta-Camuñas et al.
Fabiola Pabón-González et al.